Skip to main content

Table 2 Univariate analysis of factors associated with mortality among HIV-infected adults on antiretroviral therapy

From: Factors associated with 36-month loss to follow-up and mortality outcomes among HIV-infected adults on antiretroviral therapy in Central Kenya

 Univariable Results (n = 23890)
6 months12 months24 months36 months
OR (95% CI)P valueOR (95% CI)P valueOR (95% CI)P valueOR (95% CI)P value
Gender
 Male1.77 (1.49–2.09)< 0.0011.73 (1.49–2.01)< 0.0011.67 (1.47–1.91)< 0.0011.68 (1.48–1.91)< 0.001
 FemaleRef Ref Ref Ref 
Age groups
 20–35Ref Ref Ref Ref 
 36–501.14 (0.95–1.36)0.1621.23 (1.04–1.44)0.0131.18 (1.02–1.36)0.0241.16 (1.02–1.33)0.028
 51+1.41 (1.08–1.85)0.0121.57 (1.25–1.99)< 0.0011.58 (1.29–1.94)< 0.0011.57 (1.29–1.91)< 0.001
Marital Status
 Single1.3 (1.01–1.68)0.0431.35 (1.08–1.68)0.0081.36 (1.13–1.64)0.0021.34 (1.12–1.6)< 0.001
 Divorced1.96 (1.58–2.43)< 0.0011.80 (1.49–2.18)< 0.0011.76 (1.49–2.08)< 0.0011.79 (1.53–2.11)< 0.001
 MarriedRef Ref Ref Ref 
 Widowed1.34 (1.01–1.77)0.0431.19 (0.92–1.53)0.1861.29 (1.04–1.60)0.0231.3 (1.05–1.61)0.014
BMI
 < 18.51.96 (1.56–2.47)< 0.0011.85 (1.52–2.26)< 0.0011.82 (1.53–2.17)< 0.0011.79 (1.52–2.11)< 0.001
 18.5–24.9Ref Ref Ref Ref 
 25–29.90.50 (0.32–0.78)0.0020.54 (0.36–0.81)0.0030.57 (0.41–0.8)0.0011.10 (0.63–1.94)0.001
 30+0.37 (0.17–0.81)0.0130.45 (0.24–0.85)0.0130.53 (0.31–0.91)0.020.54 (0.34–0.88)0.013
CD4
 0–2502.35 (0.39–14.22)0.3542.23 (0.45–11.11)0.3291.42 (0.48–4.23)0.5281.52 (0.51–4.49)0.453
 251–5000.91 (0.14–5.83)0.9230.94 (0.18–4.77)0.9380.57 (0.18–1.74)0.3200.66 (0.22–2.00)0.460
 Above 500Ref Ref Ref Ref 
Regimen Started
 D4T-basedRef Ref Ref Ref 
 ABC-based0.77 (0.38–1.57)0.4760.59 (0.29–1.2)0.1460.50 (0.26–0.98)0.0420.44 (0.23–0.86)0.016
 AZT-based0.82 (0.65–1.02)0.0760.80 (0.66–0.98)0.1470.73 (0.61–0.87)< 0.0010.69 (0.58–0.82)< 0.001
 TDF-based0.50 (0.39–0.63)< 0.0010.50 (0.40–0.61)0.1480.49 (0.41–0.59)< 0.0010.48 (0.40–0.57)< 0.001
WHO Stage clinical stage at ART initiation
 Stage IRef Ref Ref Ref 
 Stage II1.56 (1.03–2.37)0.0361.57 (1.07–2.30)0.021.56 (1.11–2.18)0.011.50 (1.09–2.06)0.012
 Stage III3.37 (2.23–5.10)< 0.0013.32 (2.29–4.82)< 0.0013.10 (2.26–4.25)< 0.0012.84 (2.11–3.83)< 0.001
 Stage IV8.18 (5.38–12.44)< 0.0017.68 (5.27–11.20)< 0.0017.25 (5.23–10.04)< 0.0016.41 (4.68–8.78)< 0.001